Polypharmacology in Precision Oncology: Current Applications and Future Prospects.
Over the past decade, a more comprehensive, large-scale approach to studying cancer genetics and biology has revealed the challenges of tumor heterogeneity, adaption, evolution and drug resistance, while systems-based pharmacology and chemical biology strategies have uncovered a much more complex interaction between drugs and the human proteome than was previously anticipated. In this mini-review we assess the progress and potential of drug polypharmacology in biomarker-driven precision oncology. Polypharmacology not only provides great opportunities for drug repurposing to exploit off-target effects in a new single-target indication but through simultaneous blockade of multiple targets or pathways offers exciting opportunities to slow, overcome or even prevent inherent or adaptive drug resistance. We highlight the many challenges associated with exploiting known or desired polypharmacology in drug design and development, and assess computational and experimental methods to uncover unknown polypharmacology. A comprehensive understanding of the intricate links between polypharmacology, efficacy and safety is urgently needed if we are to tackle the enduring challenge of cancer drug resistance and to fully exploit polypharmacology for the ultimate benefit of cancer patients.
Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
Albert A
AA
Antolin
Paul
P
Workman
Jordi
J
Mestres
Bissan
B
Al-Lazikani
D000970:Antineoplastic Agents / Q000494:pharmacology*; D058492:Drug Repositioning; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D008495:Medical Oncology; D009369:Neoplasms / Q000188:drug therapy*; D064798:Polypharmacology
D000970:Antineoplastic Agents
Polypharmacology; biomarker; multi-target
drug design.; off-target; precision oncology; side-effects; systems pharmacology; target profiling
Nat Biotechnol. 2005 Mar;23(3):329-36
15711537
Nat Chem Biol. 2009 Sep;5(9):616-24
19690537
Biochim Biophys Acta. 2015 Jan;1855(1):1-16
25446042
Nature. 2009 Nov 12;462(7270):175-81
19881490
Science. 2001 Aug 3;293(5531):876-80
11423618
Bioorg Med Chem Lett. 2009 Aug 1;19(15):4102-6
19527930
Science. 2002 Jul 5;297(5578):63-4
12098689
Nat Rev Drug Discov. 2007 Sep;6(9):734-45
17690708
Cancer Discov. 2015 Aug;5(8):806-20
26193902
Curr Pharm Des. 2016;22(21):3097-108
26907947
Breast Cancer Res Treat. 2012 Jun;133(3):1057-65
22418700
Chem Res Toxicol. 2016 Apr 18;29(4):637-48
26952164
N Engl J Med. 2014 Nov 20;371(21):1963-71
25264305
Nature. 2014 Apr 10;508(7495):222-7
24695225
Nat Rev Drug Discov. 2013 Jan;12(1):35-50
23274470
Cancer Discov. 2011 Jun;1(1):78-89
22328973
Nat Chem Biol. 2015 Dec;11(12):973-980
26502155
Biochemistry. 2010 Dec 7;49(48):10267-76
21058655
Cancer Res. 2007 May 1;67(9):4408-17
17483355
Nat Chem Biol. 2014 Apr;10(4):305-12
24584101
Oncotarget. 2014 May 30;5(10):3023-8
24632590
J Clin Oncol. 2012 Mar 10;30(8):863-70
22215748
Clin Cancer Res. 2015 May 15;21(10):2289-96
25695690
J Chem Inf Model. 2013 Feb 25;53(2):279-92
23312010
Blood. 2007 Dec 1;110(12):4055-63
17720881
N Engl J Med. 2012 Nov 29;367(22):2075-88
23190221
Nat Chem Biol. 2015 Jan;11(1):19-25
25383758
Nat Rev Clin Oncol. 2015 Dec;12(12):732-42
26483297
Ann Hematol. 2015 Apr;94(4):717-9
25380996
J Proteomics. 2011 Nov 18;74(12):2554-74
21621023
J Clin Oncol. 2016 Jun 20;34(18):2165-71
27044931
Mol Cancer Ther. 2015 Oct;14(10):2292-302
26294741
Drug Discov Today. 2015 Jun;20(6):652-8
25596550
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1419-20
26917690
Clin Cancer Res. 2016 May 15;22(10):2351-8
26673800
Nat Rev Drug Discov. 2011 Dec 01;10(12):897-8
22129984
Cancer Cell. 2015 Jan 12;27(1):85-96
25500121
J Clin Oncol. 2011 Dec 20;29(36):4803-10
22042947
Oncotarget. 2016 May 31;7(22):33111-24
27105527
Clin Cancer Res. 2012 Aug 1;18(15):4104-13
22693356
Nat Rev Drug Discov. 2005 Jan;4(1):13-4
15690599
N Engl J Med. 2002 Aug 15;347(7):481-7
12181402
J Med Chem. 2014 Dec 11;57(23):9832-43
25383915
Mol Cancer Ther. 2011 Jun;10(6):1028-35
21482694
Cell. 2009 Mar 6;136(5):823-37
19269363
Nature. 2009 Nov 12;462(7270):167-8
19907483
Clin Pharmacol Ther. 2011 Nov;90(5):662-5
21975349
Gastroenterology. 2005 Feb;128(2):270-9
15685537
Nat Chem Biol. 2008 Nov;4(11):691-9
18849971
Nature. 2016 Apr 14;532(7598):166-8
27075079
Nucleic Acids Res. 2016 Jan 4;44(D1):D938-43
26673713
Science. 2013 Jul 5;341(6141):84-7
23828940
Blood. 2013 May 2;121(18):3703-8
23502220
Nat Chem Biol. 2012 Nov;8(11):905-912
23023260
ACS Chem Biol. 2015 Dec 18;10(12):2687-96
26390252
Br J Pharmacol. 2007 Sep;152(1):9-20
17549047
Expert Opin Drug Discov. 2015 Dec;10(12):1315-31
26328768
Clin Cancer Res. 2008 Jul 1;14(13):4027-31
18593977
Nat Rev Drug Discov. 2002 Jul;1(7):493-502
12120256
Leukemia. 2016 Apr;30(4):947-50
26055304
Nature. 2015 Mar 5;519(7541):102-5
25686603
Ann Oncol. 2014 Jul;25(7):1384-1390
24827134
Curr Opin Pharmacol. 2013 Aug;13(4):486-96
23810823
J Thorac Oncol. 2015 Jul;10(7):e55-7
26134233
Nat Biotechnol. 2006 Jul;24(7):805-15
16841068
Cancer Cell. 2014 Sep 8;26(3):305-306
25203318
Clin Cancer Res. 2015 Oct 15;21(20):4586-96
26085511
Nat Rev Cancer. 2005 Jan;5(1):65-72
15630416
J Med Chem. 2013 Nov 27;56(22):8955-71
23919353
Nat Rev Clin Oncol. 2013 Oct;10(10):551-2
23959269
Nat Rev Drug Discov. 2006 Sep;5(9):717-8
17001803
Clin Cancer Res. 2015 Sep 15;21(18):4212-23
26015515
Nat Biotechnol. 2012 Jul 10;30(7):679-92
22781697
Lung Cancer. 2013 Oct;82(1):171-2
23932362
Clin Cancer Res. 2009 Nov 15;15(22):6862-70
19861442
Blood. 2013 Apr 18;121(16):3165-71
23430109
Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7
21948594
Nature. 2012 Dec 13;492(7428):215-20
23235874
Curr Pharm Des. 2003;9(11):891-902
12678873
Nat Rev Drug Discov. 2004 Apr;3(4):353-9
15060530
Nat Rev Cancer. 2010 Jul;10(7):514-23
20535131
Curr Pharm Des. 2014;20(1):23-36
23530504
J Med Chem. 2011 Sep 22;54(18):6342-63
21812414
Lancet Oncol. 2015 May;16(5):550-60
25882987
J Biol Chem. 2007 Feb 9;282(6):3428-32
17178722
Clin Pharmacol Ther. 2013 Mar;93(3):252-9
23361103
Curr Opin Drug Discov Devel. 2003 Jul;6(4):470-80
12951810
Nature. 2015 Nov 26;527(7579):477-83
26550826
N Engl J Med. 2012 Feb 9;366(6):489-91
22256780
Neoplasia. 2013 Aug;15(8):975-88
23908597
AAPS J. 2012 Dec;14(4):759-63
22826034
Clin Cancer Res. 2011 Sep 15;17(18):6061-70
21810917
Drug Discov Today. 2016 Jan;21(1):82-89
26272035
Nat Rev Drug Discov. 2002 Aug;1(8):637-41
12402503
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6
20679242
Cancer Cell. 2015 Mar 9;27(3):382-96
25759023
Cancer Discov. 2015 Nov;5(11):1210-23
26482930
Cancer Discov. 2012 Oct;2(10):922-33
22956644
Cancer Discov. 2013 Feb;3(2):138-40
23400472
Nat Commun. 2016 Mar 24;7:11040
27010513
Nature. 2012 Jun 06;486(7401):80-4
22678283
Clin Cancer Res. 2015 Feb 15;21(4):833-43
25501124
ACS Chem Biol. 2015 Feb 20;10(2):395-400
25365788
PLoS One. 2012;7(4):e35582
22558171
Nat Rev Drug Discov. 2013 Dec;12(12):889-90
24287764
Nucleic Acids Res. 2014 Jan;42(Database issue):D1040-7
24304894
Nat Biotechnol. 2007 Oct;25(10):1119-26
17921997
Chem Res Toxicol. 2015 Oct 19;28(10):1875-87
26360911
N Engl J Med. 2002 Aug 15;347(7):472-80
12181401
Nat Chem Biol. 2013 Jan;9(1):3-6
23238671
Sci Transl Med. 2012 Feb 8;4(120):120ra17
22277784
J Clin Endocrinol Metab. 2013 May;98(5):E811-9
23526464
Lancet Oncol. 2015 Dec;16(16):1700-10
26596672
Cell. 2015 Jul 16;162(2):441-451
26186195
J Med Chem. 2004 Jan 29;47(3):550-7
14736236
Nat Biotechnol. 2008 Sep;26(9):983-4
18779805